These meetings, which began in 1985, emphasize the relationships between toxicity, cell injury, and carcinogenesis. It is becoming increasingly evident that new paradigms are needed to explain that an increasing number of "non-mutagenic" agents result in carcinogenesis, that cell injury, repair, and inflammation are constant companions of cancer development, and that what has been termed "tumor promotion" is a very complex issue. Recent developments in cancer genetics, including the role of tumor suppressor genes, underline this principle. With these facts in mind, we organized this year's Workshop to plan the 1991 Conference. It became apparent that much more information is needed on the basic aspects ofcell injury as related to cell replication, terminal differentiation, and chromosome anomalies, including the fundamental aspects of DNA replication, repair, and differentiation. Although the process of cell division is complex and will continue to require study in special models, it also became apparent at this Workshop that we need to look at human cells as well.
ABSTRACTS

DNA Replication and Genetic Recombination
Mechanisms: Why are They Relevant to our Understanding of the Cancer Cell? B. M. ALBERTS, Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143-0448 I shall argue below that a detailed knowledge of DNA replication and genetic recombination mechanisms-including knowledge of the structure and function of all of the proteins that mediate these processes-are very likely to be directly relevant to future approaches to the treatment of cancer. What do we know at present about these two central genetic processes?
In my laboratory, we have chosen to concentrate on understanding the group ofproteins that function on the DNA ofbacteriophage T4, a large DNA virus of rather mysterious origin: its DNA polymerase and the type II DNA topoisomerase are distinctly eukaryotic in origin, even though its known hosts are prokaryotes. We believe that the DNA metabolism of this organism provides a good model for understanding the analogous processes in other cells, including those of humans (1) .
The T4 helix-destabilizing (SSB) protein (the gene 32-protein), the T4 DNA polymerase (the product of gene 43), and 5 other T4-induced proteins (the products of genes 41, 44, 45, 61, and 62) are the fundamental components of the machine that moves a replication fork. In an in vitro reaction requiring all 7 of these purified proteins (plus deoxyribo-and ribonucleoside triphosphates), replication forks move through purified double-stranded DNA templates with near in vivo rates and fidelities.
At the replication fork, the DNA is synthesized on leading (continuous) and lagging (discontinuous) strands. The 44/62 and 45 proteins are part of a DNA polymerase "holoenzyme" and are termed "polymerase accessory proteins"; there is one holoenzyme on the leading strand and one holoenzyme on the lagging strand (1) . The gene 41 protein is a DNA helicase that uses GTP hydrolysis energy to move rapidly along the DNA; it forms a moving complex known as the "primosome" with the gene 61 protein, which is the primase that synthesizes the pentaribonucleotide primers that start each Okazaki fragment on the lagging strand. The experiments of Jack Barry in my laboratory have revealed that there is a continuous recycling of the DNA polymerase molecule on the lagging strand at the fork. This recycling is believed to involve a direct connection between the 2 DNA polymerase holoenzyme complexes present at the fork, creating a compact replication protein complex. This complex works as a unit; for example, primer synthesis appears to be delayed until the lagging strand DNA polymerase molecule in the complex finishes its previous Okazaki fragment and is released from the DNA to start the next fragment. We, therefore, view this protein complex as a protein machine (1) .
Other protein machines operate to catalyze genetic recombination processes. The central protein in the recombination pathways ofT4 bacteriophage is the T4 uvsX protein, a recA-like protein that coasts a DNA single-strand and catalyzes the synapsis of that strand with a homologous stretch of DNA double helix, forming a 3-stranded structure known as a "D-loop." In the T4 system, additional proteins, known from genetic and biochemical experiments to function in recombination processes, include the uvsY protein (an accessory protein that binds to DNA and nucleates the assembly of the uvsX protein-DNA filament), the 59 protein (which binds to uvsX-protein-coated DNA to assemble the 41 protein onto this DNA), and the 41 and dda proteins (2 DNA helicases). In in vitro reactions containing various combinations of these proteins and the DNA replication proteins, we have been able to reconstruct several reactions that link DNA replication and recombination processes (2; Barry J, Morrical S, and Alberts B, unpublished).
We now understand 15 ofa total ofabout 40 DNA binding proteins synthesized at early times of T4 bacteriophage infection. Many of the other 25 proteins are undoubtedly involved in interesting reactions ofDNA replication and genetic recombination that are not even foreseen at present. Eventually, we hope to pursue the function of all of the additional T4 proteins involved in the recombination and replication aspects ofT4 DNA metabolism, with the hope of achieving a complete understanding of the multiple protein machines involved.
As we have learned more and more about human tumors, it has become clear that they originate by a long, elaborate process that involves many serial rounds of mutation followed by natural selectionan unfortunate Darwinian competition among somatic cells. Both human lung cancers and colon cancers (4) now seem to contain on the order of 10-20 mutations per cell by the time that the tumors become fully malignant. Some of these mutations are in proto-oncogenes (converting them to oncogenes) and others are in tumor-suppressor genes (eliminating their growth-suppressing activity).
How is it possible to have 10-20 different mutations accumulate in a single cell lineage, given the enormously high fidelity with which DNA sequences are normally maintained? I believe that it is not possible, and that one of the early events that is selected for during the origin of most tumors is a loss of fidelity in the replication and/or recombination ("DNA metabolism") functions of the cell. This then allows for an unusually facile accumulation of subsequent mutations in that cell lineage.
The particular change in DNA metabolism that decreases fidelity will no doubt be different for different tumor cells. Ifwe could identify the exact change in each tumor, we might well be able to take advantage ofthe loss in fidelity to design a sophisticated chemical treatment (presumably a combination of drugs) that would kill a patient's tumor cells specifically. Unfortunately, our knowledge of the details of replication and recombination processes is still too incomplete-especially in human cells. However, recent progress in our understanding of DNA replication and recombination, including rapid progress in analyses of the human replication enzymes (3), should soon make it possible to begin to test for alterations in many of the proteins that mediate these two processes in tumors. As we learn more about DNA metabolism, this type of investigation would seem to provide an even more promising avenue for research aimed at curbing cancer. Mitosis and the equapartitioning ofchromosomes in eukaryotic cells requires the integrated function of a dynamic system of microtubules (MTs), microtubule organizing centers (MTOCs), regulatory components and "motors," collectively called the mitotic apparatus (MA). Aneuploidy, a deleterious condition whereby cells gain or loose selected chromosomes from a monoploid set during mitosis or meiosis, is probably caused by aberrations in the structure and function of the MA due to random errors in assembly or insult from environmental toxins. Therefore, an understanding of the MA and the molecular basis of chromosome distributions is essential to defining the etiology and mechanisms of aneuploidy. In this presentation, we will review the current state of knowledge of the structure and dynamics ofthe MA with special emphasis on MTs and their interaction with the kinetochore and spindle poles. Recent progress in identifying the nature and location of mitotic motors will also be presented.
Kinetochore
Recently, considerable progress has been made in understanding the structure and function of the kinetochore. In addition to being a specialized structure required for the attachment of spindle microtubules to chromosomes, kinetochores may be the site for the mitotic motor, or force-producing molecules required for prometaphase congression, metaphase alignment and anaphase movement. Patients with the autoimmune disease, scleroderma CREST, contain autoantibodies which bind to kinetochores of chromosomes in a variety of eukaryotic cells including those from plants and invertebrate and vertebrate species. These unique probes have enabled us to identify and characterize a small family of proteins localized specifically in the centromere/kinetochore region. Through the use of a newly synthesized azido-tubulin derivative as a photo-activated chemical crosslinker (1), we have been able to assign a function to one CREST antigen, the 80 kD or CENP-B antigen, as a tubulin-associated protein with a microtubule-associated protein (MAP)-binding motif. The 80 kD antigen has also been identified as DNA-binding protein by Masumoto et al (3) .
Ifkinetochores indeed contain autonomous "motors" capable of pulling chromosomes along a MT track, they should retain this function even when detached and isolated from the rest of the genome. Using the procedure of Schlegel and Pardee (4), we have succeeded in detaching the complete complement of kinetochores from unreplicated chromosomes ofChinese hamster ovary cells and have demonstrated autonomous kinetochore movement in situ as described by Brinkley et al (2) . Moreover, we will present evidence that the detached kinetochores are, in fact, subunits of a tandem array of MT binding domains, which comprise the "plate" of the metaphase chromosomes. Each subunit is a functional motile unit which retains the capacity to bind MTs, associate in pairs, align on the metaphase plate and undergo anaphase movement. A tandem repeat model for kinetochore structure will be presented which can explain various features of chromosome structure, evolution, and the organization ofdiffuse, holocentric, and localized kinetochores found in various species of eukaryotic cells.
Spindle Poles and Pericentriolar Material
The centrosome is the site for the assembly and growth of a dynamic array of cytoplasmic MTs. During mitosis, the duplicated centrosomes serve as spindle poles and generate MTs which are either captured at their (+ )ends by kinetochores or overlapped at their (+ )ends with MTs extending from opposite poles (interpolar MTs). Normal movement, alignment and segregation of chromosomes require dynamic MTs with specified polarities; (+)end at kinetochore or equator, (-)end at poles.
We will present evidence that some chemical aneugens (DES, estradiol, colcemid, nocodazole and vinblastine) can alter spindle MT polarity by disrupting the centrosome and dispersing centrioles and pericentriolar material. The latter are "captured" by kinetochores but remain functional as MTOCs. Such capture may lead to reverse spindle MT polarity, (-)end at kinetochore, (+ )end at the spindle pole. Thus, pericentriolar dissemination, resulting from mitotic arrest, may explain many aspects of druginduced aneuploidy. The human ETS genes, first identified in our laboratory, are highly conserved, being found and expressed in lower organisms like Drosophila and sea urchin, as well as in the vertebrates, including chicken, mammals and humans. In mammals, the ETS genes are structurally distinct, located on separate chromosomes; they are transcriptionally active and differentially regulated. The ETS2 encoded protein is phosphorylated and turns over with a half-life of approximately 20 min. After activation with the tumor promoter, TPA, the level of ETS2 elevates 5-to 20-fold. The properties ofthe ETS2 gene product, such as its nuclear localization, phosphorylation, rapid turnover, and response to protein kinase C, indicate that this protein belongs to a group of oncogene proteins thought to have regulatory functions in the nucleus. Alignment of the predicted ets proteins suggests that three domains exist. The domain closest to the carboxy-termini is highly conserved in all predicted gene products from species ranging from human to Drosophila. The domain located at the amino-terminal end ofthe ets proteins is more divergent, being highly conserved only between the same gene isolated from different species (e.g., chicken ets-l vs human ETS-l; mouse ets-2 vs human ETS-2). The central domain of the ets proteins is found to be most divergent, even between genes. Thus, ets represents a family of genes whose members are diverging at variable rates.
In the mouse thymus ets-l and ets-2 are 8-to 10-fold higher, respectively, in the CD4+ subset than in other subsets examined, suggesting a role in T-cell development for these genes. When quiescent T-cells are stimulated to proliferate with either crosslinking TCRlCD3 receptors, or with a combination of PM A and ionomycin, ets-2 mRNA is induced by 5-to 1O-fold, whereas ets-l mRNA is reduced to basal level. Cells transfected with the cellular ets-2 gene, expressing higher levels of ets-2 products showed a stimulated proliferation response, abolished their serum requirement and formed colonies in soft agar that could induce tumors in nude mice. Collectively, these data suggest that this family of genes might playa role in controlling specific steps of the signal transduction pathway. Thus, the ets genes, as with other genes having homology to viral oncogenes, might be instrumental in regulating cellular growth and differentiation. The events leading to skin cancer development in mice can be operationally divided into at least 3 major stages: initiation, promotion, and progression. The first stage is thought to involve an irreversible alteration in some aspects ofgrowth control and/or differentiation, possibly by activating the Haras oncogene in epidermal stem cells (3). Many different chemical carcinogens as well as ultraviolet light (UV) when given at a subcarcinogenic dose(s) can effectively initiate the development of skin tumors. Most of the chemical carcinogens that are used as initiators must first be metabolized by the mixed-function oxidase system to electrophilic intermediate(s) before they are active (3) . A direct free radical mechanism appears to be involved in UV initiation. A number ofagents based on their mechanism of action have been found to inhibit skin tumor initiation (3). In general, agents that inhibit the metabolic activation ofcarcinogens, increase the detoxification of carcinogens, scavenge the electrophi lie intermediates and free radicals from carcinogens, and inhibit cell division have been found to counteract skin tumor initiation.
In an attempt to find highly specific and effective inhibitors of the initiation stage of carcinogenesis, we decided to investigate mechanism-based irreversible inactivators (suicide inhibitors) of carcinogen metabolism. We first prepared and tested a series of aryl acetylenes as suicide substrate inhibitors of the P 450 isozymes responsible for activating polycyclic aromatic hydrocarbons (PAHs) such as benzo(a)pyrene (B(a)p) and 7, 12-dimethylbenz(a) anthracene (DMBA). Based upon analysis of the inhibition ofB(a)P metabolism in liver microsomes, we further tested l-ethynylpyrene (EP), l-vinylpyrene (VP), and 2-ethynylnaphthalene (EN) as inhibitors of B(a)P and DMBA covalent binding to epidermal DNA and tumor initiating activity in mouse skin. EP in a dose-dependent manner was found to be a very effective inhibitor of both DMBA and B(a)P binding to DNA and skin tumor initiating activity. It should be noted that EP was much more effective against DMBA than B(a)P. Application of VP also inhibited B(a)P and DMBA covalent binding to DNA and skin tumor initiating activity in a dose-dependent manner, although higher doses of VP were required than does of EP. EN was ineffective as an inhibitor of the binding and tumor initiating activity of either DMBA or B(a)P. Topical application of either EP, VP, or EN had no effect on the skin tumor initiating activity ofa direct acting initiator such as Nemethyl-N'cnitro-Ncnitrosoguanidine (MNNG). The data suggest that the pyrene moiety of EP and VP is needed to direct binding preferentially to the active sites .of P 450 isozymes involved in PAH activation and that the ethynyl group of EP is also needed to function additionally as a mechanism-based irreversible inactivator.
Although the suicide substrate EP is a very effective inhibitor ofPAH carcinogenic activity, a combination ofa PAH suicide substrate, an antioxidant, and a chemical to scavenge the electrophilic intermediate(s) ofPAH(s) may be a rational and effective approach to a complete counteraction of the tumor initiation stage by PAHs.
The skin tumor promotion and progression stages are characterized by selective and sustained cell proliferation, differentiation alterations, and genetic in-TOXICOLOGIC PATHOLOGY stability leading to the specific expansion ofthe stem cells into papillomas and carcinomas (2, 3) . Because of their mechanism of action, a number of effective inhibitors ofthe skin tumor promotion and/or progression stages has been found. Antioxidants, free radical scavenging agents, anti-inflammatory agents, inhibitors ofcell proliferation, and agents that counteract prostaglandin and polyamine synthesis are generally effective in counter-acting these stages (1-3). We recently found that the ethylester of glutathione was more effective than glutathione in inhibiting both the skin tumor promotion and progression stages (1) . This may be related to the ability ofthe ethylester of glutathione to enter the cell. We also noted that parasulfoxyphenyl acetyl dihydroalanine (AD-l 9), a potent free radical scavenging agent, was effective in preventing the formation of carcinomas during the tumor promotion and progression stages. AD-19 was also effective in suppressing TPAinduced hyperplasia but not TPA-induced ornithine decarboxylase activity.
In other studies, we observed that a combination of butylated hydroxyanisole, butylated hydroxytoluene, vitamin E, and l3-carotene, given at moderately low doses, effectively suppressed the skin tumor promotion and progression stages. Each ofthese agents, when given alone rather than in combination, produced only a low or marginal tumor inhibition.
In conclusion, a number of effective mechanismbased inhibitors have been found to counteract the initiation, promotion and/or progression stages of skin carcinogenesis. A rational and effective approach to counteracting the induction of cancer by environmental agents may well be the administering of a combination of agents that inhibit the different stages of carcinogenesis.
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Oxidants are Carcinogens
Oxidants are ubiquitous in our aerobic environment and produced in a multitude of autoxidative and metabolic reactions in mammalian organisms. Many xenobiotics are irritants and cause the immigration into tissues of phagocytes which release large amounts of activated forms of oxygen. There is convincing evidence that oxidants playa role in carcinogenesis from experiments in animals and cell culture and from epidemiology.
Oxidants playa role at several stages in carcinogenesis (3). They damage DNA and induce hereditary changes in the DNA sequence which can affect cancer-related genes. In addition, oxidants and other agents which induce "cellular stress" modulate the expression of several classes of genes. Of particular interest is the induction ofimmediate early genes which need to be expressed for the acquisition of growth competence by quiescent cells.
Two principal alternatives can be distinguished for the promotional action of oxidants: a) specific subpopulations may differ in their susceptibilities to the cytostatic and cytotoxic effects of oxidants. In support of this alternative, we found that the cytostatic effect of active oxygen and DNA strand breakage were more pronounced in the nonpromotable JB6 clone 30 than in the promotable JB6 clone 41 (1); b) oxidants and cellular prooxidant states represent signals for the selective induction of differentiation or growth in a particular subpopulation ofcells. Indeed, a burst ofextracellular active oxygen induced the competence-related proto-oncogenes c-fos and c-myc in mouse epidermal cells JB6 (4).
Growth stimulation of "initiated" cells is the hallmark oftumor promotion and the elucidation ofthe mechanisms of the induction of these genes by oxidants is of fundamental importance. In many "real life" situations, we may be dealing with a combination of these alternatives.
The Role ofthe Cellular Antioxidant Defense in Oxidant Carcinogenesis
The cellular antioxidant defense is bound to modulate the effects of oxidants. Therefore, we compared the antioxidant capacity of promotable and nonpromotable mouse epidermal cells JB6. We found that the promotable clone 41 contained 2-3 times higher mRNA concentrations and activities for catalase (CAT) and Cu.Zn-superoxide dismutase (SOD). We propose that small variations in the fine balance between toxicity and the induction of growth-related genes determine whether the overall effect of active oxygen treatment is growth stimulation or inhibition.
In order to corroborate this model, we have al-tered the enzymatic antioxidant defence in mouse epidermal cells by genetic means. Our results with stable transfectants of mouse epidermal cells JB6 (clone 41) indicate that, at comparable levels ofglutathione peroxidase, the balance between CU,Zn-SOD and CAT is a determining factor for the sensitivity to a burst ofextracellular active oxygen (AO). CU,Zn-SOD overproducers were hypersensitive to retardation of growth and cell killing by AO while CAT overproducers were protected. Both SOD and CAT diminished the induction of the growth-related proto-oncogene c-fos, albeit probably for different reasons. Transfection of SOD-overproducers with CAT partially restored the wild-type properties of parent cells. It appears that cells are stimulated to grow when they are protected from excessive AOtoxicity but when a sufficient AO-signal remains to activate the necessary growth pathways.
Protein Poly ADP-Ribosylation and -Phosphorylation Participate in c-fos Induction by Oxidative Stress
As AO induces DNA breakage and consequently activates ADPR-transferase and causes the poly ADPribosylation of chromosomal proteins (2) . We observed that ADPR-transferase inhibitors suppressed the AO induced increase in c-fos message and FOS protein (5). Affinity chromatography ofnon-histone nuclear proteins combined with immunoblotting indicates that FOS-protein is moderately poly ADPribosylated in response to AO. Our results indicate that poly ADP-ribosylation of chromosomal proteins participates in the induction of fos-message and FOS-protein but the functional significance of the poly ADP-ribosylation of FOS-protein itselfremains an open question.
It should be recognized that, besides oxidants, many classical point mutagens and carcinogenic "initiators" may also exert immediate effects on gene expression. For DNA-breaking agents, poly ADPribosylation of chromosomal proteins may play a role in the regulatory mechanism because it repr~ sents a unique link between DNA-damage and epigenetic processes. The role of cell injury and toxicity including necrosis, inflammation, and repair has been noted. This relationship seems particularly important for carcinogenic agents that are not mutagenic in vitro, e.g., Salmonella testing; however, it is also becoming a strong possibility that even mutagenic agents (ionizing radiation or chemicals) may, in fact, produce neoplasia by other mechanisms.
One possible link between cell injury and growth control is cellular ion deregulation, including [Ca 2+ L [H+L [Na+L [K+Land [Mg2+1 (7) (8) (9) . Ofthese, [Ca2+1 and [H+] are of particular importance because of their established roles in transmembrane signalling, including both cell division and cell differentiation (10).
Following many types of acute injury, [Ca 2+1 increases dramatically, often in less than I min and often in the perinuclear region. Depending on the type of injury, [Ca2+1 reaches at least 1-2 #LM within 10-15 min, especially following injuries that directly increase cell membrane permeability, e.g., sulfhydryl reagents (HgCI 2, NEM, PCMBS) or oxidant stress (H 202, xanthine-xanthine oxidase) (8, 9) . In fact, [Ca2+1 may be even higher, as 1-2 #LM saturates Fura 2, the fluorescent indicator dye. These increases of [Ca 2+1 are associated with cytoplasmic blebbing (5), disruption of the cytoskeleton, single strand breaks in DNA, clumping ofnuclear chromatin, and swelling of mitochondria. Cytoplasmic blebbing oc- In summary, oxidant stress induces a number of early changes in rat PTE, NHBE, BEAS-2B, and JB6 cells. One of the earliest changes is an increase of [Ca2+]; which appears to result in cytoplasmic blebbing (alteration ofthe cytoskeleton via modification of cytoskeleton), mitochondrial swelling (activation of phospholipases), and production of single strand breaks in DNA via the activation of calcium-dependent endonucleases. We hypothesize that the single strand breaks, in tum, result in c-fos activation, possibly through poly-ADP-ribosylation and! or protein kinase-induced protein phosphorylation (2) . All of these events, beginning with increased [Ca2+L appear to be much more extensive in normal cells than in promotable or neoplastic cells, thus giving a growth advantage to the latter. [Supported by NIH DKl5440 and Navy NOOOI4-88-K-0427.] In contrast to the classical view of chemical carcinogenesis involving direct modification of genomic DNA through the formation of adducts, there is increasing evidence that certain compounds initiate the process ofneoplastic transformation through epigenetic or non-genotoxic mechanisms. With many of these chemical agents, tumor formation is observed only following exposure to toxic doses. Our laboratory has been interested in the nephrotoxicity and nephrocarcinogenicity of glutathione and cysteine conjugates of halogenated organic solvents. Recent studies examining the renal cellular effect of S-( 1,2,3,4,4-pentachlorobutadienyl)-L-cysteine (PCBC; the cysteine conjugate of hexachlorobutadiene) indicate that the DNA damage caused by this and related compounds involves an indirect mechanism associated with cytotoxicity.
The toxicity of this class of cysteine conjugates involves the formation ofa reactive species through the activity of the enzyme, renal cysteine conjugatẽ -lyase (~-lyase; equation 1), followed by binding of the reactive fragment to cellular macromolecules [for review see (1)]. 3 + pyruvate (1) In the case of glutathione conjugates,~-lyase metabolism is preceded by the conversion of the glutathione conjugate to the corresponding cysteine conjugate by the enzymes of the pre-mercapturate pathway (v-glutamyl transferase and cysteinylglycine dipeptidase). Several of the parent haloalkenes have been shown to be renal carcinogens. For example, hexachlorobutadiene has been shown to result in a significant increase in the incidence ofrenal tumors following chronic oral administration to rats (4, 5) . Since glutathione conjugation represents the major route of hexachlorobutadiene metabolism, it would appear that the glutathione and cysteine (PCBC) conjugates represent procarcinogenic species. Indeed, PCBC has been shown to be mutagenic in prokaryotic test systems. However, in both bioassays, a strong association was observed between HCBD nephrotoxicity and the development ofrenal tumors. That is to say, tumors were only seen at dose levels that resulted in marked renal injury. Due to this, and the fact that only low levels of[14C]HCBD binding to rat kidney DNA could be demonstrated (5), it was concluded that there was an epigenetic or non-genotoxic component to the carcinogenicity of polyhalogenated alkenes such as HCBD. This conclusion is supported by recent data from our laboratory. We have used alkaline elution in an attempt to investigate the genotoxic potential of a variety of toxic cysteine conjugates (including PCBC) in primary cultures of rat proximal tubule cells. Our findings indicate that these compounds do induce DNA single strand breaks but only in association with cytotoxicity. This suggests that the mechanism of cysteine conjugate-induced cell injury and/or cell death may contribute to the formation of single strand breaks in this model. Previous studies in our laboratory have shown that the renal cell toxicity of PCBC is strictly dependent on~-lyase metabolism and appears to involve a direct effect on mitochondrial function and deregulation of cytosolic Ca 2 + (3, 6). More recently, we have found that PCBC-induced renal cell injury is associated with early evidence of lipid peroxidation and can be blocked by pre-treatment with the iron chelator, deferoxamine, or the lipophilic antioxidant, N,N-diphenyl-p-phenylenediamine, suggesting the involvement of an oxidative stress in this model of toxicity.
R-S-CH 2-CH-(COOH)-NH z~( RSH)H + :NH
Our current working hypothesis is that the release ofdegradative enzymes or genotoxic molecules (i.e., lipid hydroperoxides or reactive oxygen species) within the cell may indirectly result in DNA damage. Alternatively, genotoxic factors may be released from dead and dying cells which could lead to DNA damage in sublethally injured, neighboring cells. In either case, if the altered cell survives the toxic insult, it may, under the appropriate conditions, go on to display a transformed phenotype. We have recently demonstrated~-lyase-mediated cysteine conjugate toxicity using primary cultures of human proximal tubule cells suggesting that this novel form of renal bioactivation and nephrotoxicity may be relevant to man (2) .
Human Viral Hepatitis
S. M. FEINSTONE, Division ofVirology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892 Five distinct human hepatitis viruses are now recognized. These viruses are related only in that they are all hepatotropic and cause liver pathology (see Table I ). Three of these viruses have the potential to cause chronic infections but 2 cause only acute, selflimited infections. The 3 viruses causing chronic disease (hepatitis B, C and D viruses) may also result in significant chronic liver disease including cirrhosis and hepatocellular carcinoma. Infections by the viruses that cause only acute infections (hepatitis A and E viruses) result in no chronic sequela related to the liver. Hepatitis A and C will be covered here in detail as examples of acute and chronic hepatitis viruses.
Hepatitis A is a disease ofworld wide distribution with about 35,000 cases reported each year in the US. It is spread by the fecal oral route and is classically an infection of childhood; however, children rarely exhibit clinical disease. With changing socioeconomic conditions children are less frequently infected resulting in growing susceptible adult population. This results in occasional outbreaks ofdisease among adults. In Shanghai last year, there was an outbreak related to contaminated mussels in which 300,000 clinical cases were reported.
HA V is a picornavirus but is only distantly related to other members of that group by sequence identity and it is clearly not an enterovirus as it was tentatively classified. The virus is naked, about 27 nm in diameter, has a density in CsCl ofabout 1.32 g/ml and sediments at about 160 S. HAV is the only hepatitis virus to grow reliably in cell culture. In general, it produces no cytopathic effect and sets up persistent infections in continuous cell lines of primate origin. HAV replication seems to have no effect on host cell protein or RNA synthesis. The cell culture systems have allowed the development of both classic killed and live attenuated whole virus vaccines that are presently in clinical trials.
The virus has a genome organization like that of the other picornaviruses (3). The genome consists of single stranded RNA of about 7,435 bases in length, the genome is positive sense, it is polyadenylated at its 3' end, has a viral coded protein termed VPg covalently attached to its 5' end but no cap structure. The genome has a single open reading frame that begins 735 bases from the 5' end and is terminated about 100 bases from the 3' end. Sequences in the 5' noncoding region seem to be very important for replication and translation. The 4 viral structural proteins are coded in the 5' 113 of the genome. The non-structural region codes for probably 2 proteases, a polymerase and several other proteins ofunknown function. The genome has little sequence identity with other picornaviruses except in certain highly conserved regions. Full length cloned cDNA is infectious which has allowed for studies using mutagenesis for genetic analysis (4) .
The hepatitis C virus (HCV) is the recently recognized virus that causes parenterally transmitted non-A and non-B hepatitis (2) . While the virus itself has not been isolated in the classic sense, its genome has been cloned as cDNA, characterized, and partially expressed to make antigens useful in diagnostic assays (5) .
Clinically, HCV causes a disease that is frequently mild during the acute stage. Unfortunately this virus has a strong tendency to cause chronic infections. At least half of patients exposed by blood transfusion develop chronic infections and liver disease. Many patients who were diagnosed as having cryptogenic cirrhosis have now been shown to have HCV infections. The relationship of HCV to hepatocellular carcinoma (HCC) is rapidly becoming apparent (l). In several studies, a large proportion of patients with HCC have antibody to HCV. In some areas, many ofthese patients also have been infected with HBV. It is possible that the 2 viruses act synergistically to cause cancer which might explain why 2 populations that have similar HBV infection rates have very different HCC rates.
The HCV genome is approximately 10,000 bases in length, is single stranded RNA and the genomic RNA is the coding or positive sense. The genome organization is similar to flaviviruses, but there is little sequence identity with this class of viruses. In addition, the genome seems to be significantly shorter than most flaviviruses. Alignments of the HCV genome with other flaviviruses suggest that the structural proteins, particularly pre M, E and NS 1 may have different structures compared to typical flaviviruses.
Research on HCV is now in its infancy. The central questions concerning this virus, namely, how it establishes chronic infections and what is the mechanism of tumorigenesis, are the subject of investigation in several laboratories. In spite of extensive efforts to develop alternative short-term or in vitro assays to identify potential chemical carcinogens, the most definitive method continues to be long-term assays in rodents. Although many in vitro assays have been developed and evaluated, the majority have application only to the identification of mutagens (3) . While a high percentage of mutagens are carcinogens (~70%), a significant proportion of carcinogens are not mutagens (~30%). Therefore, the discrimination of noncarcinogenic mutagens and nonmutagenic carcinogens represent 2 important aspects of carcinogen assays. In addition, the successful application of in vitro mutagen assays is resulting in the introduction of more nonmutagenic chemicals into commerce and medicine. Development of the means to identify the nonmutagens that may have carcinogenic potential, thus, is becoming an increasingly important problem. The potential value of in vitro assay systems for this purpose is problematic since many nonmutagenic carcinogens induce tumors after prolonged, relatively high dose exposure, and often induce single site tumors.
The development ofmouse strains carrying stable germ-line insertions of cloned, transcriptionally altered oncogenes provides a unique target for chemical effects. Three transgenic strains developed by Leder and collaborators (1, 2) with the one genes ras, myc, and neu driven by a mouse mammary tumor virus (MMTV) promoter have been used in chemical exposure studies. p-Cresidine (2-methoxy-5-methylbenzeneamine) was used because it is a mutagenic carcinogen that induced bladder neoplasms in a bioassay in B6C3Fl mice. Since each ofthe transgenic mouse strains develop specific patterns of spontaneous neoplasms, related to regulation of the MMTV LTR, it is important to determine the pattern ofresponse at other tissue sites and to relate it to the patterns of tumors induced in the B6C3Fl strain. Reserpine, an alkaloid, induced mammary tumors and seminal vesicle carcinomas in the B6C3Fl strain. It was selected for assay in the transgenic strains because it was nonmutagenic and induced tumors at a site related to expression of the transgenes (mammary gland). The goals of these studies are to determine the relative sensitivity of the transgenic strains based upon the dose of chemical, time to tumor induction and the frequency and patterns of induced tumors. Quantitative risk assessment is finding increasing use by various regulatory and decision-making bodies in the development of polices and procedures intended to minimize health risks resulting from exposure to environmental carcinogens and mutagens. The process of risk assessment consists of 3 elements: hazard identification, dose-response assessment, and risk characterization. Exposure assessment and epidemiology are key components of the dose-response assessment, the objective ofwhich is to define dose-incidence relationships between environmental carcinogens and disease in human populations. These components are of critical importance, inasmuch as they effectively determine the quantitative features of risk estimation, when combined with animal bioassay data, extrapolation of dose-response data from animal models, and interspecies differences in response. Epidemiologic studies designed to evaluate the importance of environmental carcinogens as etiologic factors for human TOXICOLOGIC PATHOLOGY cancers are often seriously compromised by the lack ofquantitative exposure data for individuals within a population. Monitoring data on levels of specific carcinogens in environmental media are often the only exposure information available, and average population exposure is therefore the only quantitative parameter that can be calculated. This greatly limits the sensitivity with which exposure-effect relationships can be defined.
Molecular epidemiology involves the use of molecular and cellular markers of exposure as well as biological effects of chemical mutagens and carcinogens to detect and characterize exposure and response on an individual basis, and thus has the potential to increase the sensitivity and accuracy of quantitative risk assessment. Conceptually, the development and use of biomarkers for effects of environmental carcinogens are based on the sequence of molecular and cellular events resulting from exposure to these genotoxic chemicals. Methods have been developed for the detection ofexposure to carcinogens in experimental animals and humans, through detection ofthe carcinogens or metabolites of them in body fluids, or of adducts bound covalently to DNA or blood proteins (hemoglobin and albumin) (3). These methods are being used with success in detecting ambient exposures to carcinogens of several types. Determination of urinary levels of nitrosoproline has been used as an indicator of exposure to N-nitroso compounds, and the same approach has been used to detect metabolites of aflatoxin Bl (AFBl) and the N7-guanine adduct as markers of exposure to this dietary hepatocarcinogen (4). Detection of adducts formed between carcinogens and hemoglobin has been reported in studies of people exposed occupationally to ethylene oxide, where 3-hydroxyhistidine and 3-hydroxyvaline have been measured, and in smokers, whose hemoglobin has been found to contain levels of 4-aminobiphenyl and 3-hydroxyvaline that were correlated with frequency of cigarette smoking (2) . Albumin adducts of AFB 1 have been identified in exposed populations, and their levels correlated with ingested amounts of carcinogen. DNA adducts of carcinogens have also been detected in cells and tissues of exposed individuals. Immunoassays and physicochemical methods have been used to detect adducts formed with benzo(a)-pyrene, through the 7,8 diol-9,10 epoxide (BPDE). BPDE adducts have been found in the peripheral leukocytes of workers in foundries, aluminum manufacturing plants, and coke-oven plants, and also in roofers and cigarette smokers. The method of 32P-postlabeling has also been used successfully for detection of carcinogen-DNA adducts in placentas, peripheral leukocytes and oral mucosal cells of cigarette smokers, and in general, increased total levels of adducts were reflective of elevated levels of exposure.
Important advances are also being made in the development and application of biological indicators of early effects of genotoxic exposures. Some examples of these include mutations based on altered phenotype (e.g., HPRT deficiency); altered gene product (e.g., glycophorin in RBC membranes); RFLP or translocations involving oncogene sequences; and mutations in oncogenes (e.g., RAS), or tumor-suppresser genes (e.g., p53). Chromosomal markers that have been useful for detecting damage by genotoxic agents include structural aberrations, SCEs, and aneuploidy. The presence of micronuclei in circulating erythroid cells provides an additional index of genotoxicity (1). Molecular epidemiology based on biomonitoring provides information complementary to that derived from analysis of environmental media, and because biomonitoring data can be interpreted in the context of known mechanisms of action, they are of more direct relevance to assessment of health risks. Exposure assessment strategies based on biological monitoring can, therefore, be designed to take into account exposures through multiple routes, and integrate the consequences of intermittent as well as continuous exposures. They can also provide evidence oftotal risk from multiple sources and to multiple agents. Current methodology is applicable to detection ofgenotoxic exposures, but none of the existing methods can be considered adequately validated to provide direct evidence of cancer risk. Development and validation of markers useful for prospective characterization ofgenetic risks will be greatly facilitated by further elucidation of critical genetic changes involved in carcinogenesis (3).
Human Genome Project and Advances in Biotechnology M. L. MENDELSOHN, Biomedical Sciences Division, Lawrence Livermore National Laboratory, Livermore, CA 94550 Biotechnology, molecular genetics, and molecular biology are developing at a phenomenal pace, and are probably today's most exciting and most rapidly growing areas in all ofscience. Much ofthis progress bears on cancer research, as is amply evident in this and other current cancer meetings. The subject is too vast to be covered generally; instead I will focus on the human genome project, emphasizing work of my own laboratory.
The human genome project epitomizes the brashness and optimism of biotechnology today, as well as the scale which includes the project in the list of big science, the one biological entry in this notorious cluster. US. federal funding is estimated at $60 M from NIH and $28 M from DOE in FY90, with further major increases surviving up to now in the budget process for FY91. The project is a mixture ofdiverse and integrated efforts (1) . The diverseness emphasizes investigator initiated and scattered methodological improvements in cloning, automation of DNA preparation, sequencing, computer analysis of results, and applications to genetics. The integration involves large teams in national laboratories, research institutes and universities in many countries. Essentially every human chromosome is claimed by one team or another, with chromosomes 16, 19, 21 and X probably leading the pack in attention and progress. The teams are steadily expanding the libraries ofcloned DNAs, painstakingly ordering the library fragments, systematically generating mapping information using restriction fragments, PCR, gene identification and in situ hybridization, and rapidly creating a database suitable for this wealth of information, as well as the software and machines for analyzing it appropriately.
At Livermore, we are processing 48 cosmids per working day and have analyzed over 5,000 from human chromosome 19 (6) . Three thousand cosmids are already in contigs, and 1,680 are on the tiling path, the shortest path of overlapped cosmids spanning the contigs. We estimate that the path represents 33 Mb and 51% of the chromosome. The bulk of this effort is automated, including the daily analysis of the optimal overlap of all pairs of the thousands of measured cosmids. The contigs already involve important cancer-related genes, including two oncogenes, the CEA complex, and a cluster of DNA repair genes.
Improvements in multicolor in situ hybridization now make it a routine tool for locating telomeres, placing cosmids, and orienting or ordering cosmid clusters (5, 8) . Several striking examples of remarkable molecular genetic resolution can be shown. A parallel effort is progressing rapidly to visualize DNA and its bases with the scanning tunneling microscope (STM) (4) . Ring structures of pyrimidines and purines are clearly shown in relation to graphite substrate, and we and others are working toward the intriguing possibility of reading sequence directly from strands of single stranded DNA.
PCR is playing many roles in the genome effort. PCR of a cosmid with paired primers of Alu sequences typically gives fragments of several sizes, each representing the DNA between those Alu repeats that are within PCR-range of each other (3). These fragment sizes are of great diagnostic value for confirming cosmid overlap, and are being used extensively for extending and joining contigs. Sequenced tagged sites, STS, are a novel way to store and describe the genome. Given distributed collections of such unique primers, any defined region of the genome is potentially available to any investigator by PCR. The ability of the method to amplify DNA from minute, even single-copy, samples, also allows it to be used to produce probes from specific, morphologically determined regions of chromosomes using microdissection (7) .
Two critical areas for further development are tractable methods for cloning fragments larger than cosmids, and improvements in the reliability, speed and cost of sequencing. Yeast artificial chromosomes, YAKs, have the potential to reach megabase size, but have so far been erratic and technically difficult to use. Phage methods can already double cosmid size, and may soon expand another 5-fold.
A new method involving F plasmids of E. coli suggests the possibility of megabase sizes. Progress is being made as well in sequencing, such as improved polymerases and an automated sequencing system that is capable of sequencing a cosmid per week; but much more is needed before large-scale sequencing of the genome will be feasible.
The pace of development is easily to the point where economies ofscale make systematic genomics more economical than the gene by gene approaches of yesteryear. Current timetables speak to a fully ordered genome in 5 years (2), but this may be a bit optimistic. 
